Vaccinia Immune Globulin (VIG) is Cangene's first biodefense product licensed by the US Food & Drug Administration (FDA). VIG contains specific antibodies to the vaccinia virus (the virus used to make smallpox vaccine) and is intended for the treatment for adverse reactions that may occur following administration of the smallpox vaccine. VIG is a critical component for national biodefense programs.
Cangene was awarded a five-year contract by the United States Centers for Disease Control and Prevention (CDC) to develop and supply VIG. The contract specified a maximum of 100,000 doses of VIG to be ordered on an as-needed basis. Cangene has completed supply of the first order under this contract.
VIG was subsequently approved by the FDA in May 2005.
Cangene has also supplied this product to several other government organizations.
Botulism Antitoxin (BAT) is an investigational product containing neutralizing antibodies to the seven botulinum toxin types: A, B, C, D, E, F, and G. In May 2006, the US Department of Health & Human Services (DHHS) awarded Cangene a five-year, $362M contract under Project Bioshield. The contract requires Cangene to manufacture and supply 200,000 doses of BAT and to apply for and receive licensure from the US Food and Drug Administration (FDA). Cangene has initiated clinical and non-clinical studies in support of product licensure and has completed the first delivery of finished product under this contract.
Anthrax Immune Globulin (AIG) is an investigational antibody derived from donors immunized with the Anthrax vaccine. The DHHS awarded Cangene a contract to supply AIG for use in preliminary efficacy testing and in July, 2007, exercised its option to purchase 10,000 doses of anthrax immune globulin ("AIG"). The contract also requires that Cangene apply for and receive authorization for marketing from the U.S. Food and Drug Administration ("FDA").
SARS Immune Globulin is an R&D product containing antibodies to the virus that causes severe acute respiratory syndrome.
Cangene was awarded a contract for this project from the National Institute of Allergies and Infectious Diseases, part of the National Institutes of Health. Product was delivered to the NIH in October 2007, which completed Cangene’s requirements under the contract.
Burkholderia antibody is an early stage product containing antibody to preventing or diagnosing Burkholderia.
Cangene received funding for this project from the National Institute of Allergies and Infectious Diseases, part of the National Institutes of Health.
Ebola/Marburg antibodies are early stage monoclonal and polyclonal antibody products to treat or prevent hemorrhagic fever caused by Ebola or Marburg viruses.
Cangene received funding for this project from the Canadian government's Chemical, Biological, Radiological and Nuclear incident, Research & Technology initiative (“CRTI”).
PEG-GM-CSF is a chemically modified version of Cangene's Leucotropin(R), Granulocyte-macrophage colony-stimulating factor (GM-CSF), a proprietary version of the white-blood-cell stimulating protein. This project is in early stages of development to treat the depletion of white-blood-cells caused by radiation exposure.
Cangene received funding for this project from the Canadian government's Chemical, Biological, Radiological and Nuclear incident, Research & Technology initiative (“CRTI”) and is partnering with Health Canada 's Nuclear Emergency Preparedness and Response Division on this project. An earlier CRTI-funded project indicated that PEG modification of Leucotropin(R) was effective in lengthening the duration of GM-CSF activity, which could mean less frequent dosing is required.
|
